FDA Approves ACTOplus met(R) XR Tablets issue 470

FDA Approves ACTOplus met(R) XR Tablets for the Treatment of Type 2 Diabetes

Another “not new” drug, but new combination added to the arsenal for treating diabetes. Takeda Pharmaceuticals North America, Inc., has announced that the FDA approved an extended-release version of the combination medication ACTOplus met(R) (pioglitazone HCl and metformin HCl) as an adjunct to diet and exercise for the treatment of Type 2 diabetes. ACTOplus met(R) XR is the only oral antidiabetic fixed-dose combination medication available with the extended-release form of metformin to help improve glycemic control in a convenient, once-daily dosing option.